AI Article Synopsis

  • The study aimed to examine p53 mutations in bladder cancer and evaluate various assays for detecting these mutations.
  • Differences in methods and tissue quality may lead to inconsistent results regarding genetic alterations in the p53 gene.
  • The findings showed a strong link between p53 overexpression and mutations, with immunohistochemistry (IHC) proving to be a highly accurate method (90.3%) for detecting these mutations in clinical samples.

Article Abstract

The objective of this study was to characterize the pattern of p53 mutations in bladder cancer. The sensitivity and specificity to detect these mutations using clinical material was assessed for the following assays: immunohistochemistry, restriction-fragment-length polymorphism, single-strand-conformation polymorphism, and sequencing. Discrepancies of reported results aimed at the identification of genetic alterations in the p53 gene may be due to differences in methodology, as well as to deficient morphological evaluation of the source of tissue utilized. In order to address these critical issues, we have implemented a novel experimental design that permits analysis by molecular genetics and immunopathology techniques in any given tissue specimen, allowing morphological correlation with genotypic and phenotypic characteristics of the tissue analyzed. Forty-two patients affected with bladder tumors in whom paired normal and tumor tissues were available were used for the present study. Nuclear immunoreactivities were observed in 26 out of 42 bladder tumors analyzed. Abnormal shifts in mobility were noted in 14 of the 42 cases in distinct exons, with one tumor revealing 3 mutations. There was a strong association between p53 nuclear over-expression and 17p LOH, as well as p53 nuclear over-expression and detection of mutations by SSCP and sequencing. According to receiver-operating-curve statistical analysis, the accuracy of detecting p53 mutations by IHC was estimated to be 90.3%. It is our conclusion that, when properly used, this is a highly sensitive and specific method with simple application using clinical material.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.2910560309DOI Listing

Publication Analysis

Top Keywords

p53 mutations
12
bladder cancer
8
clinical material
8
bladder tumors
8
p53 nuclear
8
nuclear over-expression
8
p53
6
mutations
5
mutations human
4
bladder
4

Similar Publications

Molecular Mechanisms of Synergistic Effect of PRIMA-1 and Oxaliplatin in Colorectal Cancer With Different p53 Status.

Cancer Med

January 2025

Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, People's Republic of China.

Background: The toxicity and drug resistance associated with oxaliplatin (L-OHP) limit its long-term use for colorectal cancer (CRC) patients. p53 mutation is a common genetic trait of CRC. PRIMA-1 (APR-246, eprenetapopt) restores the DNA-binding capacity of different mutant P53 proteins.

View Article and Find Full Text PDF

Objective: Breast cancer is a widely prevalent and life-threatening malignancy that affects women worldwide. The identification of novel molecular markers associated with tumor progression is highly important for enhancing early detection, tailoring treatment approaches, and monitoring therapeutic outcomes. In this study, we investigated the expression patterns of four long noncoding RNAs (lncRNAs): USP30 antisense RNA1 (USP30-AS1), ELFN1 antisense RNA1 (ELFN1-AS1), GAS8 antisense RNA1 (GAS8-AS1), and small nucleolar RNA host gene 11 (SNHG11).

View Article and Find Full Text PDF

FLT3 Inhibitors Induce p53 Instability, Driven by STAT5/MDM2/p53 Competitive Interactions in Acute Myeloid Leukemia.

Cancer Lett

January 2025

Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. Electronic address:

FLT3 mutations are present in one third of patients with Acute myeloid leukemia (AML) and stand as an attractive therapeutic target. Although FLT3 inhibitors demonstrate clinical efficacy, the drug resistance remains challenging attributed to multiple mechanisms. In this study, we found that tyrosine kinase inhibitors (TKIs) targeting FLT3 prompt p53 degradation in AML cells with FLT3-ITD through ubiquitination.

View Article and Find Full Text PDF

Primary Hepatocellular Carcinosarcoma: A Case Series and Literature Review.

Clin Res Hepatol Gastroenterol

January 2025

Department of Hepatobiliary Surgery, General Hospital, Shijiazhuang, Hebei, P. R. China.

Introduction: Hepatocellular carcinosarcoma (HCS) is a rare and aggressive liver tumor with limited clinical evidence due to its infrequency. This case series aimed to enrich the existing knowledge on the diagnosis and clinical management of HCS.

Methods: Four patients with HCS were evaluated, focusing on their symptoms, diagnoses, treatments, and outcomes.

View Article and Find Full Text PDF

Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression.

Gastric Cancer

January 2025

Department of Medical Oncology, Hospital Clinico Universitario, INCLIVA, Biomedical Research Institute, University of Valencia, Avenida Menendez Pelayo nro 4 accesorio, Valencia, Spain.

Introduction: Gastric cancer (GC) burden is currently evolving with regional differences associated with complex behavioural, environmental, and genetic risk factors. The LEGACy study is a Horizon 2020-funded multi-institutional research project conducted prospectively to provide comprehensive data on the tumour biological characteristics of gastroesophageal cancer from European and LATAM countries.

Material And Methods: Treatment-naïve advanced gastroesophageal adenocarcinoma patients were prospectively recruited in seven European and LATAM countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!